Prodromal Lewy body disorder features in REM sleep behavior disorder with synuclein disease

Daniel Weintraub, MD;[1] Michele K. York, PhD;[2] Roseanne Dobkin, PhD;[3] Anuprita R Nair, MPH;[4] Ryan Kurth, MS;[4] David-Erick Lafontant, PhD;[4] Chelsea Caspell-Garcia, MS;[4] Roy N. Alcalay, MD;[5] Ethan G. Brown, MD;[6] Lana M. Chahine, MD;[7] Christopher Coffey, PhD;[4] Tatiana Foroud, PhD;[8] Douglas Galasko, MD;[9] Karl Kieburtz, MD;[10] Kenneth Marek, MD;[11] Kalpana Merchant, PhD;[12] Brit Mollenhauer, MD;[13] Kathleen L. Poston, MD;[14] Andrew Siderowf, MD;[1] Cristina Simonet;[15] Tanya Simuni, MD;[12] Caroline M. Tanner, MD, PhD;[6] Thomas F. Tropea, DO;[11] Aleksandar Videnovic, MD;[16] and the Parkinson's Progression Markers Initiative*[†]

*See Appendix

[†]All authors contributed equally to this work.

Abstract

Isolated rapid eye movement sleep behavior disorder (iRBD) is a prodromal state for Lewy body disorders, with the highest likelihood of long-term conversion to a clinical diagnosis of either Parkinson's disease (PD) or dementia with Lewy bodies (DLB). There is heterogeneity in the neuropathophysiology of iRBD that may have prognostic significance regarding the ultimate clinical features, and previous research has not focused on iRBD biologically defined as having neuronal synuclein disease (NSD) present.

Parkinson's Progression Markers Initiative (PPMI) is a longitudinal, observational, multi-center natural history study. PPMI participants with recently-diagnosed, polysomnogram-confirmed iRBD and who were cerebrospinal fluid neuronal α-synuclein seed amplification assay positive without a clinical diagnosis of PD or DLB, were examined for the clinical characteristics of prodromal PD and DLB, including mild cognitive impairment (MCI), subthreshold parkinsonism, and a range of neuropsychiatric, autonomic and sensory symptoms, and compared with a group of internal, robust healthy controls (HCs). iRBD participants (N=197) performed worse cognitively than the HC group (N=136), including on a cognitive summary score (p<0.0003, effect size = 0.41). In addition, the iRBD group was more likely to have subthreshold parkinsonism (odds ratio = 24.5, p<0.0001), neuropsychiatric symptoms (odds ratio = 3.5, p<0.0001), autonomic symptoms (odds ratio = 7.2, p<0.0001) and sensory symptoms (odds ratio = 13.2, p<0.0001) compared with the HCs. In the iRBD group, the most common symptoms or features were hyposmia (75%), pain (54%), urinary problems (52%), constipation (49%),

lightheadedness (40%) and anxiety (36%). In contrast, rates of mild cognitive impairment (MCI; 32%), subthreshold parkinsonism (27%) and psychosis (7%) were lower. iRBD participants with an abnormal dopamine transporter SPECT scan (DaTscan) had higher anxiety scores and more frequent antidepressant use than those with a normal DaTscan. Only 10% of iRBD participants met diagnostic criteria for prodromal DLB criteria due to the requirement for MCI as a defining feature. However, treating MCI as just one of five possible clinical domains, multi-domain impairment in wide-ranging combinations affected the majority of iRBD participants.

In summary, persons with iRBD and positive CSF neuronal α-synuclein testing, but without a clinically-diagnosed neurodegenerative disorder, have cognitive deficits of moderate effect size, and also have elevated rates of subthreshold parkinsonism and symptoms across neuropsychiatric, autonomic, and sensory domains, compared with healthy controls. These findings highlight the importance of assessing multiple clinical domains and symptoms in early biologically-defined synuclein disease without a formal neurodegenerative disease diagnosis, and not anchoring diagnostic criteria solely to motor symptoms or cognitive impairment.

Author affiliations:

1. Departments of Psychiatry and Neurology, Pearlman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
2. Department of Neurology, Baylor College of Medicine; Houston, TX 77030, USA
3. Department of Psychiatry, Rutgers University; New Brunswick, NJ 08901, USA
4. Department of Biostatistics, University of Iowa; Iowa City, IA 52246, USA
5. Movement Disorders Division, Tel Aviv Sourasky Medical Center; Tel Aviv, Israel; Columbia University Irving Medical Center, New York, NY
6. Department of Neurology, University of California San Francisco; San Francisco, CA 94143, USA
7. Department of Neurology, University of Pittsburgh; Pittsburgh, PA 15213, USA
8. Department of Medical and Molecular Genetics, Indiana University; Indianapolis, IN 46202, USA
9. Department of Neurosciences, University of California; San Diego, CA 92093, USA
10. Department of Neurology, University of Rochester; Rochester, NY 14618, USA
11. Institute for Neurodegenerative Disorders, New Haven, CT 06510, USA
12. Department of Neurology, Northwestern University; Chicago, IL 60611, USA

13. Department of Neurology, University Medical Center Göttingen, Göttingen, Germany and Paracelsus-Elena Klinik, Kassel, Germany
14. Department of Neurology, Stanford University; Stanford, CA 94305, USA
15. Centre for Preventive Neurology, Wolfson Institute for Population Health; Queen Mary University of London, London, England
16. Division of Sleep Neurology, Massachusetts General Hospital; Boston, MA 02114, USA

Correspondence to: Daniel Weintraub

3615 Chestnut St., Philadelphia, PA19104

daniel.weintraub@pennmedicine.upenn.edu

Keywords: RBD; parkinsonism; mild cognitive impairment; dementia; neuropsychiatry

Introduction

Rapid eye movement sleep behavior disorder (RBD) is present in up to 25% of Parkinson's disease (PD) patients at disease diagnosis, increases to as high as 75% in the long-term, and occurs in up to 90% of those with dementia with Lewy bodies (DLB).[1] In DLB, RBD is a core clinical feature in the diagnostic criteria,[2] and in PD, RBD symptoms are associated with faster decline in cognition (both global and in numerous cognitive domains),[3] with an increased risk of conversion to dementia.[4]

In a substantial proportion of patients, RBD onset occurs before the onset of clinically-diagnosed PD or DLB, and isolated RBD (iRBD) has emerged as the prodromal feature with the highest specificity for future risk of diagnosis of a Lewy body disorder (i.e., synucleinopathy, either PD or DLB), with an overall conversion rate from iRBD to an overt neurodegenerative syndrome of approximately 75% over 10 or more years.[5,6] In addition, iRBD is associated with Lewy type α-synucleinopathy on autopsy.[7]

Over the past decade, research diagnostic criteria for both prodromal PD[8,9] and DLB[10] have been proposed, and, not surprisingly, iRBD is prominent in both criteria. In addition to a focus on iRBD, cognition,[11-13] and parkinsonism,[14] the criteria also incorporate psychiatric,[15,16] autonomic,[17,18] and sensory[16,19] symptoms, which occur more frequently in these populations compared with controls and often carry prognostic significance for predicting progression to a clinically-defined Synucleinopathy.[12,16,17,19-21] Notably, a recent study reported that among individuals with iRBD, 50% met criteria for prodromal PD and 6% for prodromal DLB, and 14% for both.[22] However, that study did not include *in vivo* biomarker assessment of neuronal α-synuclein or dopaminergic dysfunction.

RBD pathophysiology is not fully elucidated yet, but clinical and basic science suggest that α-synuclein pathology begins in the lower brainstem where REM atonia circuits are located, including the sublaterodorsal tegmental/subcoeruleus nucleus and the ventral medulla, then propagates rostrally to brain regions such as the substantia nigra, limbic system, and cortex.[23] In addition to motor and cognitive changes, persons with iRBD often show neuropsychiatric,

autonomic, and sensory signs, neuroimaging alterations, and biofluid and tissue markers of neurodegeneration.[23]

Regarding presence of biologically-defined synuclein disease, in one study 85% of participants with iRBD had a positive cerebrospinal fluid [CSF] α-synuclein seed amplification assay [SAA] test,[24] suggesting that detectable synuclein disease occurs prior to onset of significant clinical symptoms that would lead to a diagnosis of a Lewy body disorder. In idiopathic PD, examining α-synuclein SAA kinetic measures, time-to-threshold at baseline predicts cognitive decline (i.e., Montreal Cognitive Assessment [MoCA] score ≤21), including in those who are Alzheimer's disease biomarker-negative.[25]

Another biological maker of synuclein disease is dopaminergic function, often measured by dopamine transport (DAT) SEPECT imaging. In PD, mean striatal specific binding ratio (SBR) is inversely correlated with RBD symptom severity score,[26] and mean striatal SBR value decreases more over time in RBD compared with non-RBD persons.[27] Another biological marker of synuclein disease is dopaminergic dysfunction, often measured by dopamine transporter (DAT) SPECT imaging. In PD, mean striatal SBR is inversely correlated with increasing RBD symptom score,[26] and the mean striatal SBR value, especially the caudate SBR, decreases more in value over time in the PD likely-RBD group than in the PD non-likely-RBD group.[27]

The Parkinson's Progression Markers Initiative (PPMI) is a prospective cohort study that enrolls participants with prodromal PD, including iRBD. Among those enrolled in PMMI with iRBD who progress to a clinical synucleinopathy, several clinical, biofluid biomarker, and imaging features have been associated with progression. These include olfaction, depression, cognition, CSF ptau:total tau ratio,[28] cortical atrophy, [29] and dopamine transporter (DAT) SPECT imaging binding. However, research done with this cohort to date also has not included *in vivo* biomarker assessment of neuronal α-synuclein.

Another recent development is the proposal for Neuronal alpha-Synuclein Disease Integrated Staging System (NSD-ISS),[30] which has transformed our conceptualization of what previously was called prodromal PD by shifting to a biological definition of disease and allowing either

motor, cognitive, or other non-motor features to be the defining characteristics of a clinical-functional staging system, giving them equal priority from the earliest disease stages. Using NSD-ISS and applying proposed biologic and clinical anchors,[31] increasing degree of both non-motor and motor dysfunction helped drive progression from slight to mild, and mild to moderate disease stages over 5 years.[32] As another example of application of NSD-ISS, we studied hyposmics with early NSD (i.e., Stage 2, or "subtle" disease) and without motor disability, and applying a recently-developed, internally-derived cognitive summary score[33] showed that hyposmia is associated with cognitive deficits, particularly when comorbid DAT imaging deficits or comorbid iRBD was present.[34]

There is considerable heterogeneity in the pathophysiology of iRBD, and to date, no studies have specifically examined individuals with *in vivo* characterization of synuclein, who would be presumed to have the highest risk and earliest likelihood of conversion to a clinically-diagnosed synuclein neurodegenerative disorder. In this context, we present the clinical and biological characteristics of a multi-center, international cohort of individuals with PSG-confirmed iRBD and confirmed synuclein disease, including presence of symptoms across multiple clinical domains reported to be affected in prodromal PD and DLB. We hypothesized that iRBD patients would be more likely to have a wide range of symptoms across multiple clinical domains, and in varying combinations, compared with robust healthy controls.

Materials and Methods

Cohorts

Isolated RBD (*N*=197)

Data for this analysis were from the PPMI, an international, multicenter, prospective, cohort study.[35,36] The iRBD cohort were: (1) enrolled into PPMI study post-2020; (2) PSG-confirmed RBD; (3) NSD+ at baseline based on positive CSF α-synuclein SAA test (Type 1, neuronal type)(see below); (4) without a local site investigator (LSI) diagnosis of PD, dementia or other neurodegenerative disease at baseline (i.e., had to be "prodromal"); (5) not on any PD meds; and (6) without GBA1 Gaucher-causing variants. Their dopamine transporter scan (DaTscan) could be normal or abnormal.

Robust healthy controls (*N*=136)

The robust healthy controls (HCs) were a subset of PPMI participants previously described.[33,34] They were: (1) enrolled into the PPMI study as a HC at any time point; (2) excluded for having possible iRBD, defined by a score ≥ 6 on the RBDSQ, self-reporting an RBD diagnosis without PSG confirmation, or self-reporting dream enactment behavior; (3) NSD negative based on CSF α-synuclein SAA tests, with any longitudinal SAA test negative too; and (4) DaTscan negative.

Variables

Demographic

Demographic variables were biological sex, age at baseline visit, race, ethnicity, and number of years of formal education.

NSD-ISS

iRBD participants were assigned to a Neuronal alpha-Synuclein Disease Integrated Staging System (NSD-ISS) stage as previously described.[30,31]

Cognitive

The LSI completed a clinical features checklist including a single item about presence of cognitive fluctuations (yes/no) and assigned a cognitive diagnosis (normal cognition, mild cognitive impairment [MCI] or dementia) at the baseline visit, in a process previously described.[37] Other variables were Montreal Cognitive Assessment (MoCA) score[38] and a recently-developed and -utilized PPMI cognitive summary score (CSS) that is age- and sex-adjusted.[33,34]

For the scope of this study, consideration was given to several definitions of MCI: (1) MoCA score ≤ 25[39]; (2) LSI diagnosis of MCI as previously reported[40]; (3) Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS)[41] Part I Cognitive Impairment item score ≥ 1 (at least slight impairment on ordinal scale of 0-4); and (4) MDS-UPDRS Part I Cognitive Impairment item score ≥ 2 (at least mild impairment). After examining the rates of MCI generated in the iRBD and HC groups applying these four definitions, a MoCA score ≤ 25 was chosen to be most consistent with rates of MCI reported in other iRBD cohorts, as a well-

accepted cut-off for MCI,[39] and as most likely to have clinical applicability (**Supplementary Table 1**).

Motor

Motor variables were MDS-UPDRS Part II (Motor Aspects of Experiences of Daily Living) total score and MDS-UPDRS Part III total score. In addition, subthreshold parkinsonism, the motor anchor for Stage 2 in NSD-ISS, was defined as MDS-UPDRS Part III (Motor Examination) score ≥ 5, excluding the postural and action tremor items.[31]

Neuropsychiatric

Neuropsychiatric variables, of relevance to prodromal PD and DLB, were: (1) 15-item Geriatric Depression Scale (GDS-15)[42]; (2) State subscale of the State-Trait Anxiety Inventory (STAI)[43]; (3) MDS-UPDRS Part I (Non-Motor Aspects of Experiences of Daily Living) Hallucination and Psychosis item score; and (4) MDS-UPDRS Part I Apathy item score. In addition, use (yes/no) of three neuropsychiatric medication classes were recorded: (1) benzodiazepine use; (2) antidepressant use; and (3) iRBD treatment use (either clonazepam or melatonin).

Autonomic

Autonomic symptoms were presence of MDS-UPDRS Part I Urinary Problems score ≥ 1, MDS-UPDRS Part I Lightheadedness on Standing score ≥ 1, and MDS-UPDRS Part I Constipation Problems score ≥ 1.

Sensory

Sensory symptoms were presence of hyposmia (UPSIT score ≤ 15th percentile) and MDS-UPDRS Part I Pain and Other Sensations score ≥ 1.

Prodromal DLB criteria

As all individuals in the PSG-confirmed iRBD cohort had a confirmed proposed biomarker for prodromal DLB, only one additional core clinical feature beyond the essential criterion of MCI was needed to meet formal research criteria for a clinical diagnosis of probable prodromal DLB.[8] The core clinical features are fluctuating cognition, recurrent visual hallucinations, and

parkinsonism; in other words, iRBD was not allowed to count as a core clinical feature as it was already an inclusion criterion for these analyses. For our purposes, MCI was diagnosed by MoCA score ≤ 25, presence of fluctuating cognition was a "yes" response by the LSI to the "cognitive fluctuations" question, recurrent visual hallucinations was more broadly conceptualized as psychosis based on an MDS-UPDRS Part I Hallucination and Psychosis item score ≥ 1, and parkinsonism was considered to be at least "subthreshold" based on an MDS-UPDRS Part III Motor Examination score ≥ 5 (excluding postural or action tremor).

Neurobiological

Neurobiological variables were: (1) Amprion CSF neuronal α-synuclein SAA test results, as previously reported for PPMI, for determining presence of NSD[24]; (2) Dopamine transporter SPECT scan (DaTscan) results, reported as the mean striatal SBR and as reflecting dopaminergic dysfunction (yes/no) based on lowest putamen value < 75th percentile SBR applying age- and sex-adjusted norms[36]; and (3) University of Pennsylvania Smell Identification Test (UPSIT) to assess olfaction.[44] Hyposmia was defined as ≤ 15th percentile applying age- and sex-adjusted norms for the revised version of the UPSIT.[45,46]

Statistics

Descriptive statistics at baseline were presented for the iRBD participants and the robust HC groups, including frequencies (percentages) for categorical measures, and means and standard deviations (SDs) or medians and interquartile ranges (IQRs) for continuous measures. Age- and sex-adjusted statistical comparisons of characteristics between the two groups were performed using logistic regression models for categorical measures, and general linear regression models for continuous measures. The p-values from these tests were reported. The Benjamini & Hochberg method was used to control the family-wise false discovery rate at 5%. A subgroup of iRBD NSD participants with NSD-ISS Stages 3 and 4 was assessed for which clinical tracks (i.e., cognitive, motor and non-motor) contributed to those stages.[31]

Descriptive statistics were also presented separately for the DaTscan-normal iRBD participants, DaTscan-abnormal iRBD participants, and robust HCs. Pairwise comparisons were performed between DAT-positive and DAT-negative iRBD participants using Wilcoxon rank sum tests for

continuous measures, and Chi-square or Fisher's exact test as appropriate for categorical measures, and associated p-values were reported. For comparisons between robust healthy controls with DAT-negative iRBD and DAT-positive iRBD participants respectively, logistic regression models were used for categorical measures, and general linear regression models were used for continuous measures. These were adjusted for age and sex. Associated p-values were reported and the Benjamini & Hochberg method was used to control the family-wise false discovery rate at 5%.

Criteria for probable prodromal DLB were evaluated for the overall iRBD cohort and were also reported by DaTscan status. The frequencies and percentages of participants who met each criterion were reported. MCI definitions were assessed by reporting their frequencies (percentages) across the iRBD NSD cohort, and an appropriate selection was made to define the essential clinical criterion of MCI.

The comorbid clinical symptoms of prodromal DLB among iRBD participants were assessed across five core clinical feature domains, and the frequency (percentage) of participants meeting the criteria for each was reported. An UpSet plot was used to display the percentage of participants with different combinations of comorbid clinical symptoms in the iRBD cohort. Prodromal Lewy body disorder categories were reported based on the number of domains for which they met the criteria. The percentage of each clinical feature within each category was plotted on a cluster bar graph for participants with iRBD and one to four core clinical feature domains. The above analysis was repeated by applying more stringent criteria for defining the core clinical feature domains (i.e., for MDS-UPDRS Part I items having a score ≥ 2 for presence of the symptom). Odds ratios and 95% confidence intervals were reported for comparisons of the Lewy body disorder symptoms between the iRBD NSD group and the robust HC group.

Statistical analyses were performed using SAS v9.4 (SAS Institute Inc., Cary, NC; sas.com; RRID:SCR_008567). UpSet plots and bar charts were created using the "ComplexUpset" package in R Statistical Software (v 4.4.1; R Core Team 2025).

RESULTS

Characteristics of cohorts

Demographics

197 iRBD and 136 robust HC participants met inclusion criteria and were included in the analysis. iRBD participants were more likely to be male, white, and Hispanic, and were older, than the robust HC group, with a similar education level **(Table 1)**. Participants with Gaucher-causing variants for PD were excluded; there were 4 iRBD and 5 robust HC participants who had the non-Gaucher causing GBA1 genetic variants.

NSD-ISS staging of iRBD participants

As iRBD is a prodromal state for PD or DLB, it was expected that most participants would be Stage 2 at study enrollment, and 87% were. Approximately half (49%) were in Stage 2B (DaTscan abnormal), and the other half (51%) were in Stage 2A (DaTscan normal) (**Table 2**). Approximately 15% of participants were either Stage 3 (4%) or Stage 4 (10%), reflecting slight-mild clinical symptoms or functional impairment despite not having a clinically-diagnosed neurodegenerative disease. Of the 26 participants that were Stages 3 or 4, 16 met the non-motor criteria, 10 the cognitive criteria, and 4 the motor criteria (4 participants met multiple criteria) (**Supplementary Table 2**).

Clinical characteristics

The median duration of iRBD diagnosis was approximately two years, with median duration of symptoms of approximately six years (**Table 1**).

As expected, given the definition of the robust HCs and the older age of the iRBD group, MoCA scores were approximately two points lower in the iRBD group. Nevertheless, the mean score remained within the unimpaired range, and only 16% of participants were diagnosed with MCI by the site investigator. The CSS was significantly lower in the iRBD group (*z*-score difference = 0.27, *p*-value = 0.0003, effect size = 0.41).

Motor scores (MDS-UPDRS Parts II and III) were higher in iRBD than in HCs but were low overall.

The iRBD group had higher depression and anxiety scores on disorder-specific rating scales than did the HC group, and using the cut-off scores on the MDS-UPDRS Part I had higher rates of psychosis and apathy. Applying the same cut-off scores to depression and anxiety also, within the iRBD group the rates of depression, anxiety, and apathy were all higher than psychosis.

Regarding other medication use, approximately 2/3 of iRBD participants were taking a medication for their sleep disorder, and 1/4 of iRBD participants were on an antidepressant. Given possible deleterious effects of sleep medications on cognitive performance, we examined the association between treatment and cognitive scores and found no association for the MoCA (p-value =0.6946) or the CSS (p-value =0.2411).

Biological characteristics

All iRBD participants were CSF αSyn-SAA positive, while all HCs were negative, as part of the inclusion criteria (**Table 1**). As mentioned previously, approximately half (49%) of iRBD participants had an abnormal DaTscan, while no HCs did. Finally, there was a strong association between iRBD status and olfaction, with 75% of iRBD participants having hyposmia versus 6% of HCs.

Impact of dopamine system dysfunction in iRBD participants

DaTscan mean (SD) striatal SBR was 2.40 (0.44) in the normal and 1.62 (0.28) in the abnormal groups. Demographic characteristics and iRBD duration were similar for Stages 2A and 2B participants (**Table 2**). There was no impact of a positive DaTscan on cognitive performance as assessed with the MoCA, CSS, or local site investigator cognitive diagnosis. Likewise, there were no between-group differences in motor scores (MDS-UPDRS Part II or III scores). For neuropsychiatric symptoms, anxiety scores were higher in those iRBD participants with a positive DaTscan compared to those with a negative DaTscan (i.e., Stage 2B versus 2A). Although depression scores were not higher in individuals in Stage 2B compared with those in Stage 2A, antidepressant use was more prevalent in Stage 2B.

Criteria for probable prodromal Lewy body dementia

Applying the prodromal DLB criteria,[10] only 10% of iRBD participants met criteria, despite only needing to meet criterion for one core clinical feature in addition to MCI, as all participants had a positive proposed biomarker (i.e., PSG-confirmed iRBD) (**Table 3**). Even though approximately one-third (32%) of iRBD participants met the criterion for MCI, only 27% of the entire cohort met the criterion for subthreshold parkinsonism, 7% for psychosis, and 2% for fluctuating cognition. The results were similar for those in Stage 2A versus 2B.

Prevalence of symptoms across six Lewy body disorder domains in iRBD

By moving beyond existing diagnostic criteria and evaluating symptoms across a broader range of domains, including an expanded set within the neuropsychiatric domain, and assigning equal importance to non-cognitive domains and MCI, we found that individuals with iRBD exhibit a diverse spectrum of impairments.

Applying less stringent cut-offs for MDS-UPDRS items (i.e., score ≥ 1 for presence of symptom), rates of any sensory symptom, any autonomic symptom, and any neuropsychiatric symptom all exceeded 50%, higher than rates for MCI or subthreshold parkinsonism (**Table 4**). Interpreted differently, 87% of iRBD participants had at least 2 additional clinical features in other domains (**Table 4**, **Figure 1**).

Even applying more stringent cut-offs for MDS-UPDRS items (i.e., score ≥ 2 for presence of symptom), rates of sensory impairment remained very high (due to the criterion for hyposmia being unchanged), and autonomic and neuropsychiatric symptoms were of comparable prevalence to MCI and parkinsonism (**Supplementary Table 3**). Now, 55% of iRBD participants evidenced at least 2 additional clinical features in other domains (**Supplementary Table 3**, **Supplementary Figure 1**).

The UpSet plots offer a way to examine the multitude of possible additional symptom combinations in iRBD by frequency. **Figure 2** is an UpSet plot based on less stringent MDS-UPDRS cut-offs, and there were nine additional symptoms or combination of symptoms with ≥ 5% prevalence, together representing 79% of the entire cohort. **Supplementary Figure 2** is an UpSet plot based on more stringent MDS-UPDRS cut-offs, and there were six additional

symptoms or combination of symptoms with ≥ 5% prevalence, together representing 62% of the entire cohort.

Odds of domain impairment in iRBD versus healthy controls

As it is important to put the prevalence of symptoms in the iRBD cohort in context, we examined the prevalence of symptoms in parkinsonism, neuropsychiatric, autonomic, and sensory domains in iRBD compared with HCs. Symptoms in all four domains were significantly more common in the iRBD cohort compared with HCs, regardless of less or more stringent MDS-UPDRS cut-offs being applied (**Supplementary Table 4**). Although the prevalence of sensory, autonomic, and neuropsychiatric symptoms decreased among iRBD participants when more stringent cut-offs were applied, the odds ratios for the prevalence of these symptoms in iRBD compared with HCs increased. The highest odds ratios were for parkinsonism and sensory symptoms. As the iRBD participants were older and with a higher percentage of males, we reran the odds ratios for iRBD versus HCs adjusting for age and sex, and the results were similar (**Supplementary Table 5**).

Discussion

In a multi-center, international cohort, participants with iRBD and *in vivo* biomarker-confirmed synucleinopathy, but without a clinically-diagnosed neurodegenerative disease, demonstrated poorer performance than a robust healthy control group across multiple clinical domains, including cognitive, motor, neuropsychiatric, autonomic, and sensory. Typically, multiple-domain impairment combinations were observed. Clinical associations of dopaminergic deficiency as an additional biological feature were observed, notably greater neuropsychiatric comorbidity, but not parkinsonism or cognition. The most common individual symptoms or features in the iRBD group were hyposmia, pain and other sensations, urinary dysfunction, constipation, lightheadedness on standing and anxiety, whereas the core clinical features of Lewy body disorders, parkinsonism and cognitive impairment, were less common. Importantly for clinical research, we also found that existing research diagnostic criteria for prodromal Lewy body disorders[10] may be too restrictive (i.e., requiring presence of MCI) or fail to capture certain symptoms that are commonly observed in the early stage of synuclein disease.

All iRBD participants had NSD based on a positive neuronal α-synuclein SAA test, and approximately half also had evidence for dopamine system dysfunction based on their DaTscan results. Stage 2 of the NSD-ISS is meant to be a prodromal state with only subtle signs or symptoms,[30] and nearly 90% of iRBD participants were classified as Stage 2, with approximately half Stage 2B (dopamine deficiency) and half Stage 2A (no dopamine deficiency). Of those that met Stage 3 or higher, most of these individuals met the non-motor or cognitive criteria for the higher stage, highlighting the value in including functional impairment in multiple clinical domains built into the NSD-ISS at all disease stages.

Our results indicate that cognitive deficits are present in iRBD even in those individuals with a normal DaTscan. Similar findings have been seen in samples defined by other prodromal features, such as hyposmia, combined with *in vivo* synuclein assessment.[34] This suggests that the neurobiological basis for early cognitive decline in this population is in part non-dopaminergic and non-striatal, consistent with cholinergic[47] and noradrenergic[48] deficits present in iRBD, as well as Lewy body pathology observed postmortem in extra-striatal regions (e.g., brainstem, limbic system), even in individuals without a neurodegenerative disease diagnosis.[49] We found that having a positive DaTscan was associated with higher anxiety scores and antidepressant use, which is consistent with previous research showing a role for the dopamine system in affective symptoms in PD,[50] or perhaps reflecting the involvement of other brainstem nuclei (e.g., raphe) associated with affective symptoms that are affected in prodromal synuclein disease.[51,52]

One objective of our research was to determine how many iRBD participants met the research diagnostic criteria for prodromal DLB,[10] which emphasize mild cognitive impairment (MCI), fluctuating cognition, spontaneous parkinsonism, and recurrent visual hallucinations. Regarding the essential clinical feature of MCI, we found that approximately 1/3 of iRBD participants met the criterion based on the MoCA cut-off score and that their impairment on the cognitive summary score was of a medium effect size, which is consistent with previous research findings of high rates of cognitive deficits in iRBD.[11,12] However, the other core clinical features were uncommon: fluctuating cognition was observed in 2% of all participants, psychosis in 7%, and at least subthreshold parkinsonism in 27%. The low rates of parkinsonism may reflect that only 50% of iRBD participants had an abnormal DaTscan. Regardless, formal prodromal DLB criteria

was met in only 10% of iRBD participants, indicating that this prodromal syndrome, as currently defined, is uncommon in recently-diagnosed iRBD.

Maintaining an emphasis on MCI and parkinsonism while broadening the scope of prodromal Lewy body disorder symptoms to include neuropsychiatric symptoms beyond psychosis, as well as autonomic and sensory domains, revealed a substantially more complex symptom profile. All five domains were more impaired in iRBD than in the robust HC group, with the highest rate found for the sensory domain due to almost 75% of iRBD participants having hyposmia, which has been reported to be more common in iRBD than in healthy controls.[19] In addition, persons with both iRBD and hyposmia have been reported to have elevated rates of cognitive deficits, motor symptoms, depression, and apathy compared with matched controls.[53] When we applied more stringent clinical criteria, the rate of sensory impairment remained very high, and approximately 20-30% of participants had symptoms in each of the other four domains. In addition to MCI, parkinsonism, and hyposmia, elevated rates of psychiatric[54] and autonomic[55] symptoms have also been reported to occur in iRBD.

Following hyposmia, the most frequently-reported symptoms included another sensory symptom (pain), autonomic symptoms such as urinary dysfunction, constipation, and lightheadedness, as well as neuropsychiatric symptoms, primarily anxiety. In contrast, the diagnostic signs and symptoms of PD (motor) and DLB (dementia) were less prevalent, as were fluctuating cognition and psychosis. We also found that multi-clinical domain impairment was common, and in many combinations. This significant co-morbidity was despite the median duration of iRBD being only two years, which is notably shorter at study entry than previously-reported cohorts.[56-58] In summary, individuals with iRBD and biologically-defined NSD, but without a clinically-diagnosed neurodegenerative disorder, exhibit cognitive deficits of moderate effect size and show elevated rates of subthreshold parkinsonism and symptoms spanning neuropsychiatric, autonomic, and sensory domains, compared with healthy controls.

Limitations of the research worth noting are having only single items for certain symptoms (e.g., cognitive fluctuations, apathy and psychosis), defining MCI on the basis of a MoCA cut-off score, having a robust HC group that did not demonstrate cognitive impairment at baseline or

cognitive decline over the short-term, and the presence of demographic differences (i.e., age, sex, race and ethnicity) between the iRBD and HC groups. Regarding the latter point, the odds ratios for frequency of clinical domains affected in the iRBD versus the HC groups were similar when adjusted for age and sex, and cognitive summary score utilized is age- and sex-corrected.

Although PD and DLB are diagnosed by the presence of parkinsonism and dementia, our results show that in iRBD with biologically-confirmed synuclein disease, the prototypical prodromal Lewy body disorder, clinical features in other domains (i.e., psychiatric, autonomic, and sensory) are equally or more prevalent, suggesting that widespread synuclein pathology is present even in recently-diagnosed iRBD. Moreover, symptoms across all five domains occur far more frequently in iRBD than in healthy controls and often co-occur in diverse combinations. These findings highlight the importance of assessing multiple clinical domains in early or prodromal synuclein disease and not anchoring diagnostic criteria or assessment instruments solely to motor symptoms or cognitive impairment.

Data availability

Data used in the preparation of this article were obtained on Jan 21, 2025, from the Parkinson's Progression Markers Initiative (PPMI) database (www.ppmi-info.org/access-data-specimens/download-data), RRID:SCR_-006431. For up-to-date information on the study, visit www.ppmi-info.org.

This analysis was conducted by the PPMI Statistics Core and used actual dates of activity for participants, a restricted data element not available to public users of PPMI data. This analysis used DAT-SPECT and aSynSAA results for participants of the Prodromal Cohort, obtained from PPMI upon request after approval by the PPMI Data Access Committee.

Protocol information for The Parkinson's Progression Markers Initiative (PPMI) Clinical - Establishing a Deeply Phenotyped PD Cohort AM 3.2. can be found on protocols.io or by following this link: https://dx.doi.org/10.17504/protocols.io.n92ldmw6ol5b/v2.

Statistical analysis codes used to perform the analyses in this article are shared on Zenodo [10.5281/zenodo.17611026].

Funding

PPMI – a public-private partnership – is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including 4D Pharma, Abbvie, AcureX, Allergan, Amathus Therapeutics, Aligning Science Across Parkinson's, AskBio, Avid Radiopharmaceuticals, BIAL, BioArctic, Biogen, Biohaven, BioLegend, BlueRock Therapeutics, Bristol-Myers Squibb, Calico Labs, Capsida Biotherapeutics, Celgene, Cerevel Therapeutics, Coave Therapeutics, DaCapo Brainscience, Denali, Edmond J. Safra Foundation, Eli Lilly, Gain Therapeutics, GE HealthCare, Genentech, GSK, Golub Capital, Handl Therapeutics, Insitro, Jazz Pharmaceuticals, Johnson & Johnson Innovative Medicine, Lundbeck, Merck, Meso Scale Discovery, Mission Therapeutics, Neurocrine Biosciences, Neuron23, Neuropore, Pfizer, Piramal, Prevail Therapeutics, Roche, Sanofi, Servier, Sun Pharma Advanced Research Company, Takeda, Teva, UCB, Vanqua Bio, Verily, Voyager Therapeutics, the Weston Family Foundation and Yumanity Therapeutics.

Competing interests

The authors report no competing interests.

Supplementary material

Supplementary material is available at *Brain* online.

Appendix

PPMI STUDY TEAMS/CORES/COLLABORATORS FOR PUBLICATIONS

Executive Steering Committee:

Kenneth Marek, MD[1] (Principal Investigator); Caroline Tanner, MD, PhD[9]; Tanya Simuni, MD[3]; Andrew Siderowf, MD, MSCE[12]; Douglas Galasko, MD[27]; Lana Chahine, MD[41]; Christopher Coffey, PhD[4]; Kalpana Merchant, PhD[61]; Kathleen Poston, MD[40]; Roseanne Dobkin, PhD[43]; Tatiana Foroud, PhD[15]; Brit Mollenhauer, MD[8]; Dan Weintraub, MD[12]; Ethan Brown, MD[9]; Karl

Kieburtz, MD, MPH[23]; Mark Frasier, PhD[6]; Todd Sherer, PhD[6]; Sohini Chowdhury, MA[6]; Roy Alcalay, MD[36] and Aleksandar Videnovic, MD[47]

Steering Committee:

Duygu Tosun-Turgut, PhD[9]; Werner Poewe, MD[7]; Susan Bressman, MD[14]; Jan Hammer[15]; Raymond James, RN[22]; Ekemini Riley, PhD[42]; John Seibyl, MD[1]; Leslie Shaw, PhD[12]; David Standaert, MD, PhD[18]; Sneha Mantri, MD, MS[62]; Nabila Dahodwala, MD[12]; Michael Schwarzschild[47]; Connie Marras[45]; Hubert Fernandez, MD[25]; Ira Shoulson, MD[23]; Helen Rowbotham[2]; Paola Casalin[11] and Claudia Trenkwalder, MD[8]

Michael J. Fox Foundation (Sponsor):

Todd Sherer, PhD; Sohini Chowdhury, MA; Mark Frasier, PhD; Jamie Eberling, PhD; Katie Kopil, PhD; Alyssa O'Grady; Maggie McGuire Kuhl; Leslie Kirsch, EdD and Tawny Willson, MBS

Study Cores, Committees and Related Studies:

Project Management Core: Emily Flagg, BA[1]

Site Management Core: Tanya Simuni, MD[3]; Bridget McMahon, BS[1]

Strategy and Technical Operations: Craig Stanley, PhD[1]; Kim Fabrizio, BA[1]

Data Management Core: Dixie Ecklund, MBA, MSN[4]; Trevis Huff, BSE[4]

Screening Core: Tatiana Foroud, PhD[15]; Laura Heathers, BA[15]; Christopher Hobbick, BSCE[15]; Gena Antonopoulos, BSN[15]

Imaging Core: John Seibyl, MD[1]; Kathleen Poston, MD[40]

Statistics Core: Christopher Coffey, PhD[4]; Chelsea Caspell-Garcia, MS[4]; Michael Brumm, MS[4]

Bioinformatics Core: Arthur Toga, PhD[10]; Karen Crawford, MLIS[10] *Biorepository Core:* Tatiana Foroud, PhD[15]; Jan Hamer, BS[15]

Biologics Review Committee: Brit Mollenhauer[8]; Doug Galasko[27]; Kalpana Merchant[61]

Genetics Core: Andrew Singleton, PhD[13]

Pathology Core: Tatiana Foroud, PhD[15]; Thomas Montine, MD, PhD[40]

Found: Caroline Tanner, MD PhD[9]

PPMI Online: Carlie Tanner, MD PhD[9]; Ethan Brown, MD[9]; Lana Chahine, MD[41]; Roseann Dobkin, PhD[43]; Monica Korell, MPH[9]

Site Investigators:

Charles Adler, PhD[51]; Roy Alcalay, MD[36]; Amy Amara, PhD[52]; Paolo Barone, PhD[30]; Bastiaan Bloem, PhD[60] Susan Bressman, MD[14]; Kathrin Brockmann, MD[26]; Norbert Brüggemann, MD[59]; Lana Chahine, MD[41]; Kelvin Chou, MD[44]; Nabila Dahodwala, MD[12]; Alberto Espay, MD[32]; Stewart Factor, DO[16]; Hubert Fernandez, MD[25]; Michelle Fullard, MD[52]; Douglas Galasko, MD[27]; Robert Hauser, MD[19]; Penelope Hogarth, MD[17]; Shu-Ching Hu, PhD[21]; Michele Hu, PhD[58]; Stuart Isaacson, MD[31]; Christine Klein, MD[59]; Rejko Krueger, MD[2]; Mark Lew, MD[49]; Zoltan Mari, MD[56]; Connie Marras, PhD[45]; Maria Jose Martí, PhD[34]; Nikolaus McFarland, PhD[54]; Tiago Mestre, PhD[46]; Brit Mollenhauer, MD[8]; Emile Moukheiber, MD[28]; Alastair Noyce, PhD[63]; Wolfgang Oertel, PhD[64]; Njideka Okubadejo, MD[65]; Sarah O'Shea, MD[39]; Rajesh Pahwa, MD[48]; Nicola Pavese, PhD[57]; Werner Poewe, MD[7]; Ron Postuma, MD[55]; Giulietta Riboldi, MD[53]; Lauren Ruffrage, MS[18]; Javier Ruiz Martinez, PhD[35]; David Russell, PhD[1]; Marie H Saint-Hilaire, MD[22]; Neil Santos, BS[51]; Wesley Schlett[47]; Ruth Schneider, MD[23]; Holly Shill, MD[50]; David Shprecher, DO[24]; Tanya Simuni, MD[3]; David Standaert, PhD[18]; Leonidas Stefanis, PhD[38]; Yen Tai, PhD[29]; Caroline Tanner, PhD[9]; Arjun Tarakad, MD[20]; Eduardo Tolosa PhD[34] and Aleksandar Videnovic, MD[47]

Coordinators:

Susan Ainscough, BA[30]; Courtney Blair, MA[18]; Erica Botting[19]; Isabella Chung, BS[56]; Kelly Clark[24]; Ioana Croitoru[35]; Kelly DeLano, MS[32]; Iris Egner, PhD[7]; Fahrial Esha, BS[53]; May Eshel[36]; Frank Ferrari, BS[44]; Victoria Kate Foster[57]; Alicia Garrido, MD[34]; Madita Grümmer[59]; Bethzaida Herrera[50]; Ella Hilt[26]; Chloe Huntzinger, BA[52]; Raymond James, BS[22]; Farah Kausar, PhD[9]; Christos Koros, MD, PhD[38]; Yara Krasowski[60]; Dustin Le, BS[17]; Ying Liu, MD[52]; Taina M. Marques, PhD[2]; Helen Mejia Santana, MA[39]; Sherri Mosovsky, MPH[41]; Jennifer Mule, BS[25]; Philip Ng, BS[45]; Lauren O'Brien[48]; Abiola Ogunleye, PGDip[29]; Oluwadamilola Ojo, MD[65]; Obi Onyinanya, BS[28]; Lisbeth Pennente, BA[31]; Romina Perrotti[55]; Michael Pileggi, MS[55]; Ashwini Ramachandran, MSc[12]; Deborah Raymond, MS[14]; Jamil Razzaque, MS[58]; Shawna Reddie, BA[46]; Kori Ribb, BSN[28]; Kyle Rizer, BA[54]; Janelle Rodriguez, BS[27]; Stephanie Roman, HS[1]; Clarissa

Sanchez, MPH[20]; Cristina Simonet, PhD[29]; Anisha Singh, BS[23]; Elisabeth Sittig[64]; Barbara Sommerfeld MSN[16]; Angela Stovall, BS[44]; Bobbie Stubbeman, BS[32]; Alejandra Valenzuela, BS[49]; Catherine Wandell, BS[21]; Diana Willeke[8]; Karen Williams, BA[3] and Dilinuer Wubuli, MB[45]

Partners Scientific Advisory Board (Acknowledgement)

Funding: PPMI – a public-private partnership – is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including 4D Pharma, Abbvie, AcureX, Allergan, Amathus Therapeutics, Aligning Science Across Parkinson's, AskBio, Avid Radiopharmaceuticals, BIAL, Biogen, Biohaven, BioLegend, BlueRock Therapeutics, Bristol-Myers Squibb, Calico Labs, Celgene, Cerevel Therapeutics, Coave Therapeutics, DaCapo Brainscience, Denali, Edmond J. Safra Foundation, Eli Lilly, Gain Therapeutics, GE HealthCare, Genentech, GSK, Golub Capital, Handl Therapeutics, Insitro, Janssen Neuroscience, Lundbeck, Merck, Meso Scale Discovery, Mission Therapeutics, Neurocrine Biosciences, Pfizer, Piramal, Prevail Therapeutics, Roche, Sanofi, Servier, Sun Pharma Advanced Research Company, Takeda, Teva, UCB, Vanqua Bio, Verily, Voyager Therapeutics, the Weston Family Foundation and Yumanity Therapeutics.

1 Institute for Neurodegenerative Disorders, New Haven, CT
2 University of Luxembourg, Luxembourg
3 Northwestern University, Chicago, IL
4 University of Iowa, Iowa City, IA
5 VectivBio AG
6 The Michael J. Fox Foundation for Parkinson's Research, New York, NY
7 Innsbruck Medical University, Innsbruck, Austria
8 Paracelsus-Elena Klinik, Kassel, Germany
9 University of California, San Francisco, CA
10 Laboratory of Neuroimaging (LONI), University of Southern California
11 BioRep, Milan, Italy
12 University of Pennsylvania, Philadelphia, PA
13 National Institute on Aging, NIH, Bethesda, MD

14 Mount Sinai Beth Israel, New York, NY
15 Indiana University, Indianapolis, IN
16 Emory University of Medicine, Atlanta, GA
17 Oregon Health and Science University, Portland, OR
18 University of Alabama at Birmingham, Birmingham, AL
19 University of South Florida, Tampa, FL
20 Baylor College of Medicine, Houston, TX
21 University of Washington, Seattle, WA
22 Boston University, Boston, MA
23 University of Rochester, Rochester, NY
24 Banner Research Institute, Sun City, AZ
25 Cleveland Clinic, Cleveland, OH
26 University of Tübingen, Tübingen, Germany
27 University of California, San Diego, CA
28 Johns Hopkins University, Baltimore, MD
29 Imperial College of London, London, UK
30 University of Salerno, Salerno, Italy
31 Parkinson's Disease and Movement Disorders Center, Boca Raton, FL
32 University of Cincinnati, Cincinnati, OH
34 Hospital Clinic of Barcelona, Barcelona, Spain
35 Hospital Universitario Donostia, San Sebastian, Spain
36 Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
37 St. Olav's University Hospital, Trondheim, Norway
38 National and Kapodistrian University of Athens, Athens, Greece
39 Columbia University Irving Medical Center, New York, NY
40 Stanford University, Stanford, CA
41 University of Pittsburgh, Pittsburgh, PA
42 Center for Strategy Philanthropy at Milken Institute, Washington D.C.
43 12, New Brunswick, NJ
44 University of Michigan, Ann Arbor, MI
45 Toronto Western Hospital, Toronto, Canada

46 The Ottawa Hospital, Ottawa, Canada
47 Massachusetts General Hospital, Boston, MA
48 University of Kansas Medical Center, Kansas City, KS
49 University of Southern California, Los Angeles, CA
50 Barrow Neurological Institute, Phoenix, AZ
51 Mayo Clinic Arizona, Scottsdale, AZ
52 University of Colorado, Aurora, CO
53 NYU Langone Medical Center, New York, NY
54 University of Florida, Gainesville, FL
55 Montreal Neurological Institute and Hospital/McGill, Montreal, QC, Canada
56 Cleveland Clinic-Las Vegas Lou Ruvo Center for Brain Health, Las Vegas, NV
57 Clinical Ageing Research Unit, Newcastle, UK
58 John Radcliffe Hospital Oxford and Oxford University, Oxford, UK
59 Universität Lübeck, Luebeck, Germany
60 Radboud University, Nijmegen, Netherlands
61 TransThera Consulting
62 Duke University, Durham, NC
63 Wolfson Institute of Population Health, Queen Mary University of London, UK
64 Philipps-University Marburg, Germany
65 University of Lagos, Nigeria

References

1. Hu MT. REM sleep behavior disorder (RBD). *Neurobiol Dis*. Sep 2020;143:104996. doi:10.1016/j.nbd.2020.104996
2. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. *Neurology*. Jul 04 2017;89(1):88-100. doi:10.1212/WNL.0000000000004058
3. Chahine LM, Xie SX, Simuni T, et al. Longitudinal changes in cognition in early Parkinson's disease patients with REM sleep behavior disorder. *Parkinsonism Relat Disord*. Mar 12 2016;27:102-106. doi:10.1016/j.parkreldis.2016.03.006
4. Lin YQ, Chen SD. RBD: a red flag for cognitive impairment in Parkinson's disease? *Sleep Med*. Apr 2018;44:38-44. doi:10.1016/j.sleep.2018.01.006
5. Postuma RB, Iranzo A, Hu M, et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. *Brain*. Mar 1 2019;142(3):744-759. doi:10.1093/brain/awz030
6. Iranzo A, Fernandez-Arcos A, Tolosa E, et al. Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. *PLoS ONE*. 2014 2014;9:e89741. Not in File.
7. Tremblay C, Adler CH, Shill HA, et al. Predicting post-mortem alpha-synuclein Pathology by the combined presence of probable REM sleep behavior disorder and hyposmia. *Mov Disord Clin Pract*. Feb 2025;12(2):157-165. doi:10.1002/mdc3.14244
8. Berg D, Postuma RB, Adler CH, et al. MDS research criteria for prodromal Parkinson's disease. *Movement Disorders*. 2015 2015;30:1600-1611. Not in File.
9. Heinzel S, Berg D, Gasser T, et al. Update of the MDS research criteria for prodromal Parkinson's disease. *Mov Disord*. Aug 14 2019;34:1464-1470. doi:10.1002/mds.27802
10. McKeith IG, Ferman TJ, Thomas AJ, et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. *Neurology*. Apr 28 2020;94(17):743-755. doi:10.1212/WNL.0000000000009323
11. Gagnon JF, Vendette M, Postuma RB, et al. Mild cognitive impairment in rapid eye movement sleep behavior disorder and Parkinson's disease. *Ann Neurol*. Jul 2009;66(1):39-47. doi:10.1002/ana.21680
12. Arnaldi D, Chincarini A, De Carli F, et al. The fate of patients with REM sleep behavior disorder and mild cognitive impairment. *Sleep Med*. Mar 2021;79:205-210. doi:10.1016/j.sleep.2020.02.011
13. Joza S, Hu MT, Jung KY, et al. Prodromal dementia with Lewy bodies in REM sleep behavior disorder: A multicenter study. *Alzheimers Dement*. Jan 2024;20(1):91-102. doi:10.1002/alz.13386
14. Elasfar S, Hameed H, Ehgoetz Martens K. Motor features that distinguish isolated REM sleep behavior disorder patients from healthy controls: A systematic review. *J Parkinsons Dis*. Sep 1 2025:1877718X251359225. doi:10.1177/1877718X251359225
15. Gunawardana CW, Matar E, Lewis SJG. The clinical phenotype of psychiatric-onset prodromal dementia with Lewy bodies: a scoping review. *J Neurol*. Jan 2024;271(1):606-617. doi:10.1007/s00415-023-12000-w
16. Pearson J, Badenoch JB, Van Wamelen D. Using prodromal non-motor symptoms to predict Parkinson's disease onset and motor phenotype. *J Neurol Neurosurg Psychiatry*. Jun 19 2025;doi:10.1136/jnnp-2024-335429

17. Navarro-Otano J, Llanso L, Alejaldre A, Diez L, Santamaria J, Iranzo A. Autonomic nervous system dysfunction in idiopathic REM sleep behavior disorder as a short-term risk for a synucleinopathy. *J Neurol*. Dec 2 2024;272(1):1. doi:10.1007/s00415-024-12787-2
18. Ferini-Strambi L, Oertel W, Dauvilliers Y, et al. Autonomic symptoms in idiopathic REM behavior disorder: a multicentre case-control study. *J Neurol*. Jun 2014;261(6):1112-8. doi:10.1007/s00415-014-7317-8
19. Iranzo A, Marrero-Gonzalez P, Serradell M, Gaig C, Santamaria J, Vilaseca I. Significance of hyposmia in isolated REM sleep behavior disorder. *J Neurol*. Mar 2021;268(3):963-966. doi:10.1007/s00415-020-10229-3
20. van Duijvenboden S, Ramirez J, Scheurink J, et al. Heart rate profiles during exercise and incident Parkinson's disease. *Ann Neurol*. Aug 2 2025;doi:10.1002/ana.70010
21. Wang C, Chen F, Li Y, Liu J. Possible predictors of phenoconversion in isolated REM sleep behaviour disorder: a systematic review and meta-analysis. *J Neurol Neurosurg Psychiatry*. Apr 2022;93(4):395-403. doi:10.1136/jnnp-2021-328062
22. Arnaldi D, Mattioli P, Orso B, et al. The many faces of REM sleep behavior disorder. Providing evidence for a new lexicon. *Eur J Neurol*. Apr 2025;32(4):e70169. doi:10.1111/ene.70169
23. Stefani A, Antelmi E, Arnaldi D, et al. From mechanisms to future therapy: a synopsis of isolated REM sleep behavior disorder as early synuclein-related disease. *Mol Neurodegener*. Feb 11 2025;20(1):19. doi:10.1186/s13024-025-00809-0
24. Siderowf A, Concha-Marambio L, Lafontant DE, et al. Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using alpha-synuclein seed amplification: a cross-sectional study. *Lancet Neurol*. May 2023;22(5):407-417. doi:10.1016/S1474-4422(23)00109-6
25. Orru CD, Vaughan DP, Vijiaratnam N, et al. Diagnostic and prognostic value of alpha-synuclein seed amplification assay kinetic measures in Parkinson's disease: a longitudinal cohort study. *Lancet Neurol*. Jul 2025;24(7):580-590. doi:10.1016/S1474-4422(25)00157-7
26. Liu R, Umbach DM, Troster AI, Huang X, Chen H. Non-motor symptoms and striatal dopamine transporter binding in early Parkinson's disease. *Parkinsonism Relat Disord*. Mar 2020;72:23-30. doi:10.1016/j.parkreldis.2020.02.001
27. Kim YE, Kim YJ, Hwang HS, Ma HI. REM sleep behavior disorder in early Parkinson's disease predicts the rapid dopaminergic denervation. *Parkinsonism Relat Disord*. Nov 2020;80:120-126. doi:10.1016/j.parkreldis.2020.09.032
28. Ye G, Li Y, Zhou L, et al. Predictors of conversion to alpha-synucleinopathy diseases in idiopathic rapid eye movement sleep behavior disorder. *J Parkinsons Dis*. 2020;10(4):1443-1455. doi:10.3233/JPD-202243
29. Pereira JB, Weintraub D, Chahine L, Aarsland D, Hansson O, Westman E. Cortical thinning in patients with REM sleep behavior disorder is associated with clinical progression. *npj Parkinson's Disease*. 2019/05/03 2019;5(1):7. doi:10.1038/s41531-019-0079-3
30. Simuni T, Chahine LM, Poston K, et al. A biological definition of neuronal alpha-synuclein disease: towards an integrated staging system for research. *Lancet Neurol*. Feb 2024;23(2):178-190. doi:10.1016/S1474-4422(23)00405-2
31. Dam T, Pagano G, Brumm MC, et al. Neuronal alpha-Synuclein Disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohorts. *NPJ Parkinsons Dis*. Sep 27 2024;10(1):178. doi:10.1038/s41531-024-00789-w

32. Simuni T, Gochanour C, Nair AR, et al. Neuronal alpha-synuclein disease stage progression over 5 years. *Mov Disord*. Apr 30 2025;doi:10.1002/mds.30191
33. Weintraub D BM, Kurth R, York MY, and the Parkinson's Progression Markers Initiative. Use of robust norming to create a sensitive cognitive summary score in de novo Parkinson's disease: an illustrative example. *Movement Disorders*. 2025;40:468-477.
34. Weintraub D, Nair AR, Kurth R, et al. Cognitive performance in early neuronal synuclein disease with hyposmia but without motor disability: association with dopamine deficiency and isolated rapid eye movement sleep behavior disorder. *Ann Neurol*. Jul 11 2025;doi:10.1002/ana.27263
35. Marek K, Jennings D, Lasch S, et al. The Parkinson Progression Marker Initiative (PPMI). *Progress in Neurobiology*. 2011 2011;95:629-635. Not in File.
36. Marek K, Chowdhury S, Siderowf A, et al. The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort. *Ann Clin Transl Neurol*. Dec 2018;5(12):1460-1477. doi:10.1002/acn3.644
37. Caspell-Garcia C, Simuni T, Tosun-Turgut D, et al. Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. *PLoS One*. 2017;12(5):e0175674. doi:10.1371/journal.pone.0175674
38. Nasreddine Z, Phillips N, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *Journal of the American Geriatrics Society*. 2005 2005;53:695-699. In File.
39. Dalrymple-Alford J, MacAskill M, Nakas C, et al. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. *Neurology*. 2010 2010;75(19):1717-1725. Not in File.
40. Weintraub D, Picillo M, Cho HR, et al. Impact of the dopamine system on long-term cognitive impairment in Parkinson disease: an exploratory study. *Mov Disord Clin Pract*. Jun 2023;10(6):943-955. doi:10.1002/mdc3.13751
41. Goetz C, Tilley B, Shaftman S, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and climimetric testing results. *Movement Disorders*. 2008 2008;23:2129-2170. Not in File.
42. Sheikh J, Yesavage J. Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. In: TL B, ed. *Clinical Gerontology: A Guide to Assessment and Intervention*. The Haworth Press; 1986:165-173.
43. Spielberger C, Gorsuch R, Lushene R, Vagg P, Jacobs G. *Manual for the State-Trait Anxiety Inventory (Form Y)*. Consulting Psychologists Press; 1983.
44. Doty R, Shaman P, Dann M. Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. *Physiology and Behavior*. 1984 1984;32:489-502. Not in File.
45. Brumm MC, Pierz KA, Lafontant DE, et al. Updated percentiles for the University of Pennsylvania Smell Identification Test in adults 50 years of age and older. *Neurology*. Apr 18 2023;100(16):e1691-e1701. doi:10.1212/WNL.0000000000207077
46. Pierz KA, Aamodt W, Gochanour C, et al. Percentile scores for the revised University of Pennsylvania Smell Identification Test for 16,972 individuals 60 years of age and older. *NPJ Parkinsons Dis*. Oct 1 2025;11(1):280. doi:10.1038/s41531-025-01095-9
47. Kim R, Jin B, Kim H, et al. Cholinergic basal forebrain degeneration in isolated REM sleep behaviour disorder. *Brain*. May 26 2025;doi:10.1093/brain/awaf196

48. Knudsen K, Fedorova TD, Hansen AK, et al. In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study. *Lancet Neurol*. Jul 2018;17(7):618-628. doi:10.1016/S1474-4422(18)30162-5
49. Maya G, Iranzo A, Gaig C, et al. Post-mortem neuropathology of idiopathic rapid eye movement sleep behaviour disorder: a case series. *Lancet Neurol*. Dec 2024;23(12):1238-1251. doi:10.1016/S1474-4422(24)00402-2
50. Weintraub D, Newberg A, Cary M, et al. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease. *Journal of Nuclear Medicine*. 2005 2005;46:227-232. PMCID: PMC15695780. Not in File.
51. Schrag A, Horsfall L, Walters K, Noyce A, Petersen I. Prediagnostic presentations of Parkinson's disease in primary care: a case-control study. *Lancet Neurol*. 2015 2015;14:57-64. Not in File.
52. Leentjens AF, Van den Akker M, Metsemakers JF, Lousberg R, Verhey FR. Higher incidence of depression preceding the onset of Parkinson's disease: a register study. *Mov Disord*. Apr 2003;18(4):414-8. doi:10.1002/mds.10387
53. Pauly L, Rauschenberger A, Pauly C, et al. Cognition and other non-motor symptoms in an at-risk cohort for Parkinson's disease defined by REM-sleep behavior disorder and hyposmia. *J Parkinsons Dis*. 2024;14(3):545-556. doi:10.3233/JPD-230285
54. Honeycutt L, Gagnon JF, Pelletier A, Montplaisir JY, Gagnon G, Postuma RB. Characterization of depressive and anxiety symptoms in idiopathic REM sleep behavior disorder. *J Parkinsons Dis*. 2021;11(3):1409-1416. doi:10.3233/JPD-212625
55. Postuma RB, Gagnon JF, Vendette M, Montplaisir JY. Markers of neurodegeneration in idiopathic rapid eye movement sleep behaviour disorder and Parkinson's disease. *Brain*. Dec 2009;132(Pt 12):3298-307. doi:10.1093/brain/awp244
56. Iranzo A, Tolosa E, Gelpi E, et al. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. *Lancet Neurol*. May 2013;12(5):443-53. doi:10.1016/S1474-4422(13)70056-5
57. Postuma R, Gagnon J-F, Bertrand J-A, Genier D, Montplaisir J. Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. *Neurology*. 2015 2015;84:1-10. Not in File.
58. Elliott JE, Lim MM, Keil AT, et al. Baseline characteristics of the North American prodromal Synucleinopathy cohort. *Ann Clin Transl Neurol*. Apr 2023;10(4):520-535. doi:10.1002/acn3.51738

Figure legends

Figure 1. Bar graphs of frequency of comorbid clinical domains in iRBD using original criteria

Figure 2. UpSet plot of overlap of comorbid clinical features

Figure 1. Bar graphs of frequency of comorbid clinical domains in iRBD using original criteria



Figure 2. UpSet plot of overlap of comorbid clinical features